Vascular remodeling is a prominent phenotype of Pulmonary Hypertension (PH), a deadly condition with unknown causes and no known treatment. Using in vivo models of pulmonary vascular disease, our lab has identified CHI3L1 and its receptors as major contributors of PH responses. My goal is to study the mechanisms that underlie vascular remodeling in PH and develop nanoparticle-based drug delivery systems against CHI3L1 and its receptors to treat vascular remodeling in PH.